HER2 is overexpressed in 20 to 25% of invasive breast cancers, and patients with those cancers have worse overall survival and time to relapse than patients whose tumors express normal levels of HER2 [1]. The gene discussed is ERBB2; the disease is invasive breast carcinoma.